Real-world efficacy of stapokibart for severe olfactory dysfunction: early and sustained improvement independent of baseline type 2 inflammation status and nasal polyp burden - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Real-World Assessment of Stapokibart's Effectiveness for Severe Olfactory Dysfunction: Early and Lasting Improvements Regardless of Initial Type 2 Inflammation Levels and Nasal Polyp Severity

  • By

  • Xiang-Ning Cheng

  • Liu-Qing Zhou

  • Yue Zhou

  • Sha-Zhou Li

  • Shan Chen

  • Qing Cheng

  • Li-Yue Li

  • Jian-Jun Chen

  • Tao Zhou

  • June 11, 2026

Share

Clinical Report: Real-World Assessment of Stapokibart's Effectiveness for Severe Olfactory Dysfunction

Overview

This study evaluates the efficacy of stapokibart in improving olfactory dysfunction in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Significant olfactory improvements were observed as early as two weeks, with 52.5% of patients achieving normosmia by week 16.

Background

Olfactory dysfunction is a prevalent and debilitating symptom in patients with CRSwNP, affecting their quality of life. Traditional treatments have variable efficacy, highlighting the need for effective therapies. Stapokibart, an anti-IL-4 receptor monoclonal antibody, offers a novel approach to managing this condition.

Data Highlights

OutcomeWeek 0Week 16P-value
Mean Objective Olfactory Score3.05 ± 2.9811.35 ± 3.73P<0.0001
Nasal Polyp Score4.03 ± 1.701.63 ± 1.61P<0.001
Percentage Achieving Normosmia-52.5%-

Key Findings

  • Stapokibart significantly reduced smell loss VAS by Week 2 (P<0.0001).
  • At Week 16, 52.5% of patients achieved normosmia.
  • Mean objective olfactory score improved from 3.05 to 11.35 (P<0.0001).
  • Nasal polyp score decreased from 4.03 to 1.63 (P<0.001).
  • Olfactory recovery was consistent across subgroups, regardless of baseline inflammatory markers.
  • Higher baseline polyp burden correlated with faster early improvement.

Clinical Implications

The findings suggest that stapokibart may be a valuable treatment option for patients with moderate-to-severe olfactory dysfunction due to CRSwNP. Clinicians should consider its use in patients who have not responded adequately to traditional therapies.

Conclusion

Stapokibart demonstrates rapid and sustained improvements in olfactory function in CRSwNP patients, with baseline characteristics influencing the speed of recovery but not the overall outcome.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. Zhou, 2025 -- Effects of Different Types of Medications on Olfactory Dysfunction in CRSwNP: A Systematic Review and Network Meta‐Analysis
  3. Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1), PMC
  4. conexiant — Pediatric Allergic Rhinitis: When Meds Fall Short
  5. Comparable Outcomes in Nasal Symptoms After Microscopic Versus Endoscopic Transsphenoidal Surgery: Findings from a Multi-Center Prospective Study
  6. Drugs - Real World Outcomes — A Real-World Evaluation of the Efficacy of MP-AzeFlu® in Austrian Patients Suffering from Persistent Allergic Rhinitis
  7. Ophthalmology Management — Can Allergy Drops Improve Nasal Symptoms?
  8. Pediatric Allergic Rhinitis: When Meds Fall Short
  9. Comparable Outcomes in Nasal Symptoms After Microscopic Versus Endoscopic Transsphenoidal Surgery
  10. A Real-World Evaluation of the Efficacy of MP-AzeFlu® in Austrian Patients Suffering from Persistent Allergic Rhinitis
  11. https://www.entnet.org/wp-content/uploads/2025/07/CPG_ASU_SummaryGuide_V3.pdf
  12. Effects of Different Types of Medications on Olfactory Dysfunction in CRSwNP: A Systematic Review and Network Meta‐Analysis - Zhou - 2025 - The Laryngoscope - Wiley Online Library
  13. Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial - PMC

Original Source(s)

Real-world efficacy of stapokibart for severe olfactory dysfunction: early and sustained improvement independent of baseline type 2 inflammation status and nasal polyp burden

  • by Xiang-Ning Cheng, Liu-Qing Zhou, Yue Zhou, Sha-Zhou Li, Shan Chen, Qing Cheng, Li-Yue Li, Jian-Jun Chen, Tao Zhou

  • June 11, 2026

Related Content

Development and validation of a nomogram based on LASSO regression for predicting early postoperative polyp recurrence in patients with chronic rhinosinusitis with nasal polyps

Nasal Tumor Misdiagnosed as Carcinoma

Accurate histopathologic evaluation and complete excision distinguished a rare benign lesion from squamous cell carcinoma and guided management.

Higher Steroid Exposure Linked to Systemic Adverse Events in CRSwNP

Higher annual oral corticosteroid exposure was associated with greater odds of systemic adverse events, with avascular bone necrosis and pneumonia showing dose-dependent associations with cumulative dose and osteoporosis associated with longer annual exposure duration.